Canaccord Genuity has trimmed its price target for Zevra Therapeutics, citing weaker-than-anticipated sales performance across European markets. The brokerage's decision comes after the company reported revenue figures that failed to meet expectations in several key European countries, raising concerns about the pace of commercial adoption for its specialty products.
Shares of Zevra Therapeutics have come under pressure in recent trading sessions, with the stock declining approximately 4% since the start of the week. The broader biotech sector has also been volatile, with the FTSE 350 Pharmaceuticals & Biotechnology index slipping 0.6% on Monday amid a risk-off mood in global markets.
Analysts at Canaccord noted that while Zevra's core product portfolio remains promising, the European ramp-up has been slower than modelled. 'We see a more gradual uptake curve in Europe, which pushes out our revenue assumptions,' the analysts wrote in a note to clients. They maintained a 'buy' rating but lowered the price target from $12.00 to $9.50 per share.
For UK investors holding positions in US-listed small-cap pharma stocks through pension funds or investment trusts, the downgrade serves as a reminder of the risks tied to geographic revenue concentration. European regulatory hurdles and varying national reimbursement policies have historically posed challenges for smaller drugmakers seeking to scale across the continent.
The broader market context remains mixed. The FTSE 100 was trading flat on Monday at 8,215 points, while the mid-cap FTSE 250 edged up 0.2%. Defensive sectors such as healthcare have seen some rotation, but the outlook for small-cap biotech remains tied to clinical milestones and commercial execution rather than macroeconomic trends.